Gary C Starling

List of Publications by Year
in descending order

34 papers	1,889 citations	394286 19 h-index	395590 33 g-index
34 all docs	34 docs citations	34 times ranked	2366 citing authors

#	Article	IF	Citations
1	Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab. Molecular Cancer Therapeutics, 2020, 19, 1298-1307.	1.9	8
2	Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells. Journal of Immunology Research, 2017, 2017, 1-14.	0.9	11
3	Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-Î± pathways. Cancer Immunology, Immunotherapy, 2015, 64, 61-73.	2.0	123
4	Nuclear Factor ÎºB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR. Frontiers in Immunology, 2014, 4, 505.	2.2	15
5	BTNL8, a butyrophilin-like molecule that costimulates the primary immune response. Molecular Immunology, 2013, 56, 819-828.	1.0	34
6	PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis. Arthritis Research and Therapy, 2013, 15, R207.	1.6	18
7	Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunology, Immunotherapy, 2013, 62, 1841-1849.	2.0	258
8	Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. Journal of Cancer Research and Clinical Oncology, 2013, 139, 315-325.	1.2	34
9	Abstract 2722: Active recruitment of immune effector cells mediatesin vivotumor growth inhibition by enavatuzumab, an antibody to human TWEAK receptor. , 2012, , .		1
10	Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len).. Journal of Clinical Oncology, 2012, 30, 8087-8087.	0.8	5
11	Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. Journal of Neuroimmunology, 2009, 212, 65-73.	1.1	5
12	Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins. International Immunology, 2006, 18, 473-484.	1.8	19
13	Antagonism of PDGF-D by Human Antibody CR002 Prevents Renal Scarring in Experimental Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2006, 17, 1054-1062.	3.0	64
14	Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structureâ€“activity relationships. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1829-1833.	1.0	35
15	Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2955-2958.	1.0	48
16	Serum Levels of CD137 Ligand and CD178 are Prognostic Factors for Progression of Myelodysplastic Syndrome. Leukemia and Lymphoma, 2004, 45, 301-308.	0.6	14
17	Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas Ligand (CD178) expression. British Journal of Haematology, 2002, 117, 76-85.	1.2	10
18	Retinoic Acid and Vitamin E Modulate Expression and Release of CD178 in Carcinoma Cells: Consequences for Induction of Apoptosis in CD95-Sensitive Cells. Experimental Cell Research, 2001, 270, 248-258.	1.2	10

#	Article	IF	Citations
19	Soluble CD137 (4-1BB) Ligand Is Released Following Leukocyte Activation and Is Found in Sera of Patients with Hematological Malignancies. Journal of Immunology, 2001, 167, 4059-4066.	0.4	59
20	Promotion of Activated Human B Cell Apoptosis and Inhibition of Ig Production by Soluble CD95 Ligand: CD95-Based Downregulation of Ig Production Need Not Culminate in Activated B Cell Death. Cellular Immunology, 2000, 203, 1-11.	1.4	8
21	Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells. Journal of Immunology, 2000, 165, 2903-2910.	0.4	81
22	Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis, 2000, 152, 217-227.	0.4	93
23	Analysis of the Ligand Binding Site in Fas (CD95) by Site-Directed Mutagenesis and Comparison with TNFR and CD40. Biochemistry, 1998, 37, 3723-3726.	1.2	19
24	Differential Induction of Apoptosis by Fasâ€“Fas Ligand Interactions in Human Monocytes and Macrophages. Journal of Experimental Medicine, 1997, 185, 1511-1516.	4.2	242
25	Identification of Amino Acid Residues Important for Ligand Binding to Fas. Journal of Experimental Medicine, 1997, 185, 1487-1492.	4.2	70
26	Identification of the Tumor Antigen 90K Domains Recognized by Monoclonal Antibodies SP2 and L3 and Preparation and Characterization of Novel Anti-90K Monoclonal Antibodies. Biochemical and Biophysical Research Communications, 1997, 232, 367-372.	1.0	16
27	CD6â€”ligand interactions: a paradigm for SRCR domain function?. Trends in Immunology, 1997, 18, 498-504.	7.5	136
28	Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. European Journal of Immunology, 1997, 27, 1469-1478.	1.6	78
29	Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction. European Journal of Immunology, 1996, 26, 738-746.	1.6	28
30	Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. European Journal of Immunology, 1995, 25, 2064-2068.	1.6	130
31	Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells. European Journal of Immunology, 1995, 25, 2528-2532.	1.6	74
32	The Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 Contains the Activated Leukocyte Cell Adhesion Molecule Binding Site. Journal of Biological Chemistry, 1995, 270, 18187-18190.	1.6	83
33	Molecular cloning of a novel member of the immunoglobulin gene superfamily homologous to the polymeric immunoglobulin receptor. European Journal of Immunology, 1992, 22, 1157-1163.	1.6	58
34	Hairy cell leukemia cells are relatively NK-insensitive targets. Pathology, 1988, 20, 361-365.	0.3	2